Reduced side effects and more effective therapies are some of the benefits promised by pharmacogenomics. But to reach these goals, industry will have to marshal a broad range of skills.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lewis, R. An individual approach. Nat Biotechnol 23, 1317–1318 (2005). https://doi.org/10.1038/nbt1005-1317
Issue Date:
DOI: https://doi.org/10.1038/nbt1005-1317